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Background: The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic
arthritis (PsA). We evaluated the effect of guselkumab on fatigue.
Methods: Across two phase 3 trials of guselkumab (DISCOVER-1, DISCOVER-2), patients with active PsA despite
standard therapy were randomized to subcutaneous injections of guselkumab 100mg every 4 weeks (Q4W, N = 373);
guselkumab 100mg at week 0, week 4, and then Q8W (N = 375); or placebo (N = 372) through week 24, after which
patients in the placebo group crossed over to guselkumab Q4W. Fatigue was measured as a secondary endpoint using
the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue instrument (range 0–52, higher scores indicate
less fatigue). Least-squares mean changes in FACIT-Fatigue scores were compared between treatments using a mixed-
effect model for repeated measures. Mediation analysis was used to adjust for indirect effects on fatigue deriving from
improvement in other outcomes, including ≥20% improvement in American College of Rheumatology criteria (ACR20;
prespecified), minimal disease activity (MDA; post hoc), or C-reactive protein (CRP; post hoc).
Results: Baseline mean (SD) FACIT-Fatigue scores in DISCOVER-1 (N = 381) and DISCOVER-2 (N = 739),
ranging from 29.1 (9.5) to 31.4 (10.1), indicated substantial levels of fatigue relative to the United States
general population (43.6 [9.4]). Across studies, mean improvements, and proportions of patients with ≥4-
point improvements, in FACIT-Fatigue scores at week 24 with guselkumab Q4W and Q8W (5.6–7.6 and 54–
63%, respectively) were larger vs placebo (2.2–3.6 and 35–46%). Improvement in FACIT-Fatigue scores with
guselkumab was sustained from week 24 to week 52, with moderate-to-large effect sizes (Cohen’s d =
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Rahman et al. Arthritis Research & Therapy          (2021) 23:190 Page 2 of 12of the effects of guselkumab vs placebo on fatigue were direct effect, after adjusting for achievement of
ACR20 (Q4W 69–70%, Q8W 12–36% direct effect) or MDA (72–92% across dosing regimens) response or for
change in serum CRP concentrations (82–88% across dosing regimens).
Conclusions: In patients with active PsA, guselkumab 100 mg Q4W or Q8W led to clinically meaningful and
sustained improvements in fatigue through 1 year. A substantial portion of the improvement in FACIT-
Fatigue scores induced by guselkumab was independent of effects on the achievement of other select
outcomes.
Trial registration: Name of the registry: ClinicalTrials.gov
Trial registrations: DISCOVER-1, NCT03162796; DISCOVER-2, NCT03158285
Date of registration: DISCOVER-1, May 22, 2017; DISCOVER-2, May 18, 2017
URLs of the trial registry record:
DISCOVER-1, https://clinicaltrials.gov/ct2/show/NCT03162796?term=NCT03162796&draw=1&rank=1
DISCOVER-2, https://clinicaltrials.gov/ct2/show/NCT03158285?term=NCT03158285&draw=2&rank=1
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Mediation analysisBackground
Psoriatic arthritis (PsA) is a chronic inflammatory ar-
thropathy with diverse manifestations. It can affect per-
ipheral and axial joints, be accompanied by enthesitis
and/or dactylitis, and associate with psoriasis [1]. Fatigue
is commonly experienced by individuals with chronic in-
flammatory diseases such as PsA and is associated with
disease activity, pain, sleep disturbances, and depression
[2, 3]. Fatigue is defined as a feeling of exhaustion, with
decreased capacity for physical and mental work [4]. It
includes a range of experiences, from tiredness to ex-
haustion, that can interfere with normal daily function
and reduce health-related quality of life (HRQoL). Pa-
tients with PsA consider fatigue as one of their most im-
portant symptoms [5, 6], and moderate-to-severe fatigue
is reported by up to half of PsA patients [5–9]. The im-
portance of fatigue as a treatment target is highlighted in
the European League Against Rheumatism (EULAR) rec-
ommendations for the management of PsA [10], and it
has been added to the core domains for PsA assessment
in clinical studies by OMERACT [11].
The mechanism underlying fatigue is complex and un-
defined, and it can involve physiological, psychological,
and social aspects [4]. Signs and symptoms of PsA are
effectively treated with biologics that block specific cyto-
kines and reduce inflammation. Improvement of fatigue
has also been evaluated in biologic clinical trials, with
variable measurement tools and results [12–14]. In a re-
cent report of a population-based cohort study, substan-
tial fatigue remained following tumor necrosis factor-
inhibitor (TNFi) therapy [15]. To develop new therapies
for effective treatment of fatigue in patients with PsA,
information is needed on the causality of their fatigue, as
well as efficacy associated with distinct mechanisms of
action.Guselkumab (Janssen Biotech, Horsham, PA, USA), a
high-affinity, human monoclonal antibody specific to the
interleukin (IL)-23p19-subunit, is approved to treat pa-
tients with moderate-to-severe psoriasis and active PsA
[16]. In DISCOVER-1 and DISCOVER-2, the pivotal
phase 3 studies evaluating guselkumab in patients with
PsA, guselkumab effectively treated the diverse manifes-
tations of PsA, including joint signs and symptoms,
physical function, skin disease, enthesitis, dactylitis, and
HRQoL, with maintenance of improvements through 1
year [17–19]. We now report the efficacy of guselkumab
in treating the fatigue of PsA, using a validated patient-
reported outcome (PRO) instrument, the Functional As-
sessment of Chronic Illness Therapy-Fatigue (FACIT-Fa-
tigue) [20, 21], through 1 year of DISCOVER-1 and
DISCOVER-2. Employing mediation analysis, we also
evaluated the direct effect of guselkumab on fatigue, de-
fined as the change in FACIT-Fatigue score in patients
treated with guselkumab after adjustment for select clin-
ical outcomes, including achievement of ≥20% improve-
ment in the American College of Rheumatology
(ACR20) or minimal disease activity (MDA) responses
or changes in serum C-reactive protein (CRP)
concentrations.Methods
Patients and study designs
DISCOVER-1 [17] and DISCOVER-2 [18] were phase 3,
randomized, placebo-controlled trials of guselkumab in
patients with PsA, with similar study designs. Both trials
enrolled patients with active PsA, diagnosed according
to the Classification Criteria for Psoriatic Arthritis
(CASPAR) [22], who did not respond to or were intoler-
ant of non-biologic disease-modifying anti-rheumatic
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inflammatory drugs. Active PsA was defined as ≥3 ten-
der and ≥3 swollen joints and serum CRP concentrations
≥0.3 mg/dL in DISCOVER-1 and as ≥5 tender and ≥ 5
swollen joints and serum CRP ≥0.6 mg/dL in
DISCOVER-2. Prior treatment with ≤2 TNFi was per-
mitted, but limited to approximately 30% of the study
population, in DISCOVER-1 [17]. All DISCOVER-2 pa-
tients were biologic-naïve [18].
In both studies, patients were randomized to receive
subcutaneous injections of guselkumab 100 mg at week
0 then every 4 weeks (Q4W), guselkumab 100 mg at
weeks 0 and 4 then every 8 weeks (Q8W) with placebo
at alternating 4-week intervals, or placebo Q4W. Pa-
tients in the placebo group crossed over to guselkumab
100 mg Q4W at week 24. Treatment in DISCOVER-1
continued through week 48 and in DISCOVER-2
through week 100.Assessment of fatigue
The FACIT-Fatigue instrument is a 13-item PRO vali-
dated to measure fatigue and its impact on daily activ-
ities and function during the previous week in patients
with PsA [20, 21]. Total FACIT-Fatigue scores range
from 0 to 52, with higher scores indicating less fatigue.
Clinically meaningful improvement in the FACIT-
Fatigue score is defined as a ≥4-point increase [21]. The
mean (standard deviation [SD]) FACIT-Fatigue score,
derived from limited studies in the general United States
(US) population, has been reported as 43.6 (9.4) [23].Statistical methods
Treatment failure rules were applied to analyses of FACI
T-Fatigue scores through week 24 [17, 18] and post-
week 24 [19] as previously described. Changes from
baseline through week 24 (placebo-controlled period) in
FACIT-Fatigue scores were assessed using a mixed-
effect model for repeated measures (MMRM). The
MMRM adjusted for baseline FACIT-Fatigue scores and
randomization stratification factors (baseline use of non-
biologic DMARDs [yes/no] and prior use of TNFi [yes/
no] for DISCOVER-1; baseline use of non-biologic
DMARDs [yes/no] and baseline CRP [>2.0/≤2.0 mg/dL]
for DISCOVER-2). Resulting least-squares (LS) mean
changes and surrounding 95% confidence intervals (CIs)
are reported. P values were not adjusted for multiplicity
of testing.
The effect size of observed changes from baseline in
FACIT-Fatigue scores at weeks 24 and 52 was calculated
using Cohen’s method, by dividing the change in FACI
T-Fatigue score from baseline by the SD of baseline
scores. Effect sizes of 0.20, 0.50, and 0.80 indicate small,
moderate, and large effects, respectively [24].The proportions of patients achieving clinically mean-
ingful improvement (≥4-point increase) in the FACIT-
Fatigue score [21] at week 24 were compared between
each guselkumab group and placebo using a Cochran–
Mantel–Haenszel test (with stratification as described
above); 95% CIs were derived from Wald statistics. P
values were not adjusted for multiplicity of testing.
Modified cumulative distribution curves [25] were
generated to show the proportions of patients achieving
various levels of improvement in the FACIT-Fatigue
score from ≥0 to ≥20 at week 24 by treatment group.
Mediation analysis [26, 27], as depicted in Fig. 1, was
conducted to estimate the proportion of direct treatment
effect on FACIT-Fatigue scores after adjusting for the
indirect effect mediated by improvement in other se-
lected clinical outcomes. Outcomes assessed included
achievement of ACR20, as predefined, and achievement
of the MDA composite endpoint [28] or changes in
serum CRP concentrations, as determined post hoc. The
mediation analyses employed linear regression and logis-
tic regression models with bootstrapping to determine
95% CIs. Baseline covariates included age, sex, body
mass index, baseline FACIT-Fatigue score, CRP (mg/
dL), PsA duration (years), physician’s global assessment
of disease (0–10-cm visual analog scale [VAS]), patient’s
global assessment of arthritis (0–10-cm VAS), Health
Assessment Questionnaire-Disability Index score (0–3),
patient’s assessment of pain (0–10-cm VAS), swollen
joint count (0–66), and tender joint count (0–68).
Results
Patient disposition and baseline characteristics
Of the patients enrolled in DISCOVER-1 (N = 381) and
DISCOVER-2 (N = 739), 91% and 93%, respectively,
completed treatment through 1 year. Patients random-
ized at baseline (guselkumab 100 mg Q4W, N = 373;
guselkumab 100 mg Q8W, N = 375; placebo, N = 372)
had a mean (SD) age of 46.6 (11.7), mean (SD) PsA dis-
ease duration of 5.9 (6.1) years, and substantial disease
burden (Table 1). Within each study, baseline character-
istics were generally consistent across randomized treat-
ment groups. DISCOVER-2 participants had numerically
higher levels of systemic inflammation and swollen and
tender joint counts, per study design, and also demon-
strated more skin psoriasis involvement. Mean (SD)
baseline FACIT-Fatigue scores, which were consistent
across randomized treatment groups and between the
DISCOVER-1 and DISCOVER-2 populations, ranged
from 29.1 (9.5) to 31.4 (10.1).
Changes in FACIT-Fatigue scores over time through week
52
At week 24, mean increases (improvements) in FACIT-
Fatigue scores were 5.8 and 5.6 in the guselkumab Q4W
Fig. 1 Mediation analysis. Direct effect = treatment effect on outcome independent of the effect on the mediator; indirect effect = treatment
effect on outcome that is attributed to its effect on the mediator. ACR20, ≥20% improvement in American College of Rheumatology criteria











N 128 127 126 245 248 246
Age (years) 47 (12) 49 (12) 49 (11) 46 (12) 45 (12) 46 (12)
Male, n (%) 66 (52%) 68 (54%) 61 (48%) 142 (58%) 129 (52%) 117 (48%)
BMI (kg/m2) 29.9 (5.5) 29.9 (6.4) 29.6 (5.7) 29.1 (5.9) 28.7 (6.3) 29.0 (6.4)
PsA disease duration (years) 6.6 (6.3) 6.4 (5.9) 7.2 (7.6) 5.5 (5.9) 5.1 (5.5) 5.8 (5.6)
Components of ACR20 and MDA
Number of swollen joints (0–66) 8.6 (5.8) 10.9 (9.3) 10.1 (7.1) 12.9 (7.8) 11.7 (6.8) 12.3 (6.9)
Number of tender joints (0–68) 17.7 (13.1) 20.2 (14.5) 19.8 (14.4) 22.4 (13.5) 19.8 (11.9) 21.6 (13.1)
CRP (mg/dL), median (IQR) 0.6 (0.3–1.3) 0.7 (0.4–1.9) 0.8 (0.3–1.5) 1.2 (0.6–2.3) 1.3 (0.7–2.5) 1.2 (0.5–2.6)
PASI score (0–72) 9.5 (10.1) 8.4 (9.8) 7.7 (8.8) 10.8 (11.7) 9.7 (11.7) 9.3 (9.8)
HAQ-DI (0–3) 1.1 (0.6) 1.2 (0.6) 1.1 (0.6) 1.2 (0.6) 1.3 (0.6) 1.3 (0.6)
Patient’s global assessment of arthritis (VAS 0–10) 6.1 (2.0) 6.5 (2.0) 6.1 (2.2) 6.4 (1.9) 6.5 (1.9) 6.5 (1.8)
Patient’s global assessment of pain (VAS 0–10) 5.9 (2.0) 6.0 (2.1) 5.8 (2.2) 6.2 (2.0) 6.3 (2.0) 6.3 (1.8)
Physician’s global assessment (VAS 0–10) 6.2 (1.6) 6.2 (1.7) 6.3 (1.7) 6.6 (1.5) 6.6 (1.6) 6.7 (1.5)
Patients with enthesitis, n (%) 73 (57%) 72 (57%) 77 (61%) 170 (69%) 158 (64%) 178 (72%)
Leeds Enthesitis Index score (1–6) 3.0 (1.5) 2.7 (1.6) 2.8 (1.6) 3.0 (1.7) 2.6 (1.5) 2.8 (1.6)
SF-36 PCS score (0–100) 35.9 (8.3) 34.1 (7.6) 33.8 (8.5) 33.3 (7.1) 32.6 (7.9) 32.4 (7.0)
MCS score (0–100) 46.5 (9.8) 47.0 (11.1) 48.7 (9.6) 48.4 (11.0) 47.4 (10.8) 47.2 (12.0)
FACIT-Fatigue score (0–52) 31.4 (10.1) 29.5 (11.3) 30.2 (9.9) 30.8 (9.6) 29.3 (9.9) 29.1 (9.5)
Data are mean (SD) unless otherwise indicated
ACR20 ≥20% improvement in American College of Rheumatology criteria, BMI body mass index, CRP C-reactive protein, FACIT Functional Assessment of Chronic
Illness Therapy, HAQ-DI Health Assessment Questionnaire-Disability Index, IQR interquartile range, MDA minimal disease activity, PASI Psoriasis Area and Severity
Index, PsA psoriatic arthritis, SD standard deviation, Q4W every 4 weeks, Q8W every 8 weeks, SF-36 PCS/MCS 36-item Short-Form physical/mental component
summary, VAS visual analog scale
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placebo group in DISCOVER-1; respective changes in
DISCOVER-2 were 7.1 and 7.6 vs 3.6 (all P< 0.001,
Fig. 2). Improvements were seen as early as week 8 in
the larger DISCOVER-2 study of patients with more ac-
tive disease at baseline, and by week 16 in the smaller
DISCOVER-1 study that included TNFi-experienced pa-
tients. These substantial improvements in fatigue were
maintained by guselkumab Q4W and Q8W through
week 52, at which time LS mean changes were 6.7–6.9Fig. 2 Changes from baseline in FACIT-Fatigue score through week 52 in aand 7.2–8.4 across guselkumab arms in DISCOVER-1
and DISCOVER-2, respectively (Fig. 2).
The effect sizes of guselkumab Q4W and Q8W on
changes in FACIT-Fatigue scores at week 24 were mod-
erate in DISCOVER-1 (Cohen’s d = 0.52–0.55) and large
in DISCOVER-2 (0.75–0.81); robust effect sizes were
also seen at week 52 in the guselkumab Q4W (0.68–
0.84) and Q8W (0.66–0.91) groups (Table 2).
Higher proportions of guselkumab- than placebo-
treated patients achieved clinically meaningfulDISCOVER-1 and b DISCOVER-2


















W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52 W 24 W 52
N 125 124 123 114 114 104 234 229 238 234 237 230
Observed mean change in FACIT-Fatigue score 5.6 6.9 5.9 7.5 2.6 6.6 7.0 7.7 8.0 8.9 3.8 7.5
(SD) (7.8) (8.4) (10.4) (9.6) (8.3) (9.4) (8.6) (9.1) (9.9) (9.5) (9.0) (9.4)
Cohen’s d effect sizea 0.55 0.68 0.52 0.66 0.26 0.65 0.75 0.84 0.81 0.91 0.41 0.80
FACIT Functional Assessment of Chronic Illness Therapy, Q4W every 4 weeks, Q8W every 8 weeks, SD standard deviation, W week
aThe effect size of changes from baseline in FACIT-Fatigue scores, based on the observed data, was calculated by dividing the change in FACIT-Fatigue score from
baseline by the SD of baseline scores [24]
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scores, beginning at week 8 (DISCOVER-2) or week 16
(DISCOVER-1). At week 24, significantly greater propor-
tions of guselkumab-randomized patients achieved such
improvements in FACIT-Fatigue scores when compared
with placebo, i.e., and 63% (Q4W, P< 0.001) and 54%
(Q8W, P<0.01) vs 35% in DISCOVER-1 and 60% (Q4W,
P< 0.01) and 61% (Q8W, P< 0.001) vs 46% in
DISCOVER-2. At week 52, 55–62% of patients random-
ized to guselkumab in DISCOVER-1 and 64–66% in
DISCOVER-2 demonstrated a clinically meaningful im-
provement in fatigue (Fig. 3).
Patients who switched from placebo to guselkumab
100 mg Q4W at week 24 demonstrated changes from
baseline and achievement of clinically meaningful im-
provements in FACIT-Fatigue score at week 52 compar-
able to those seen in patients originally randomized to
guselkumab (Figs. 2 and 3).
Cumulative distribution of improvements in FACIT-
Fatigue scores at week 24
As shown in Fig. 4, clear separation between both
guselkumab dosing regimens and placebo was observed
over a range of changes from baseline in FACIT-Fatigue
scores. More specifically, numerically larger proportions
of patients in both the guselkumab Q4W and Q8W vs
placebo groups achieved ≥2 to ≥12-point increases from
baseline in FACIT-Fatigue scores at week 24.
Mediation analyses
Results of mediation analyses indicated that improve-
ments in the FACIT-Fatigue score observed among
guselkumab-treated patients at week 24 were partially
mediated indirectly through achievement of ACR20 re-
sponse. With guselkumab Q4W, 69% and 70% of guselk-
umab’s impact on FACIT-Fatigue scores was
independent of effects mediated through ACR20. For
guselkumab Q8W, 12% and 36% of the effect on FACIT-
Fatigue scores in DISCOVER-1 and DISCOVER-2,respectively, was independent of those mediated by
achievement of ACR20 response. Independent treatment
effects of guselkumab on FACIT-Fatigue scores were
also observed after adjusting for other clinical outcomes,
including achievement of MDA target and change from
baseline in CRP concentration at week 24 (Table 3). The
relative magnitudes of the direct vs indirect (mediated)
effect of guselkumab on fatigue and the extent of differ-
ences between dosing regimens varied among the clin-
ical endpoints examined.
Discussion
Guselkumab provided clinically meaningful improve-
ments in fatigue among patients with active PsA who
participated in the pivotal, phase 3, DISCOVER-1 and
DISCOVER-2 trials. Guselkumab treatment effects on
changes from baseline in FACIT-Fatigue scores were ob-
served as early as week 8 in DISCOVER-2 patients, who
were biologic-naïve and demonstrated more active dis-
ease at baseline, and by week 16 in DISCOVER-1 pa-
tients, one-third of whom were TNFi-experienced. The
greater average improvements, and proportions of pa-
tients experiencing clinically meaningful improvement
(≥4 points), in fatigue seen at week 24 were maintained
in the groups of patients who continued to receive
guselkumab through week 52. Guselkumab was esti-
mated to have a moderate- (DISCOVER-1) to-large
(DISCOVER-2) effect on improving FACIT-Fatigue
scores through 1 year. Additionally, mediation analyses
demonstrated that substantial proportions of the effects
of guselkumab Q4W and Q8W vs placebo on fatigue
were direct effects, after adjusting for achievement of
ACR20 and MDA responses or change in serum CRP
concentrations.
Fatigue is common in PsA, and moderate-to-severe fa-
tigue has been reported by 30–50% of patients with PsA
[5–9]. Although this important symptom can be
neglected by physicians when assessing disease severity
in rheumatological disorders [29, 30], PsA patients
Fig. 3 Proportion of patients achieving clinically meaningful improvement in FACIT-Fatigue score (≥4-point increase [21]) through week 52 in a
DISCOVER-1 and b DISCOVER-2
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health domain impacting their life and as a top priority
for improvement [5, 6, 29]. Higher levels of fatigue in
patients with PsA have been associated with greater
work impairment, more work time missed, greater im-
pairment while performing daily activities, higher pain
scores, and diminished persistence of TNFi treatment
[15, 31]. Recently, a multinational real-world PsA study
demonstrated that, despite TNFi treatment, substantial
fatigue persisted and was significantly associated with re-
duced work productivity [32]. Such findings highlight
the importance of managing fatigue in PsA patients, aswell as the need to assess fatigue accurately and identify
effective treatment options [13].
Utilizing data derived from the 1120 PsA patients evalu-
ated in DISCOVER-1 and DISCOVER-2, we assessed pa-
tients’ fatigue via the FACIT-Fatigue scale, an instrument
that has been validated in patients with PsA [20, 21]. At
baseline, patients in both DISCOVER trials had mean
(SD) FACIT-Fatigue scores ranging from 29.1 (9.5) to 31.4
(10.1), compared with 43.6 (9.4), based on limited studies
in a US population, and 23.9 (12.6) in patients with
cancer-related anemia [23]. These data highlight the sub-
stantial levels of fatigue experienced by these PsA patients.
Fig. 4 Modified cumulative distribution curves of changes in FACIT-Fatigue score at week 24 in a DISCOVER-1 and b DISCOVER-2
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[20, 33–37]. The FACIT-Fatigue scale [20] and the Fa-
tigue Numeric Rating Scale [37] have the advantage of
being validated for PsA. Several controlled studies of bi-
ologics for PsA have evaluated fatigue using these vali-
dated scales, as well as more general scales [12, 38–43].
However, the description of results on fatigue from these
studies is typically limited in the published literature. In
a recent analysis of 880 patients with PsA and fatigue in
the DANBIO registry, less than half of the patients
achieved 50% improvement in their Fatigue VAS after 6
months of treatment with their initial TNFi [15].Similarly, in a meta-analysis of patients with active
rheumatoid arthritis, treatment with biologics was found
to lead to only small-to-moderate improvements in
fatigue [44]. Here, in addition to employing a fatigue
scale validated for PsA [20, 21], and a cut-point in
that scale that has been shown to define minimal
clinically meaningful improvement [21], we employed
modified cumulative distribution plots to demonstrate
achievement of varying levels of improvement in
FACIT-Fatigue scores. Importantly, in addition to a
greater proportion of patients in the guselkumab vs
placebo groups achieving the ≥4-point threshold of
Table 3 Mediation analysis of the effects of clinical responses on changes in FACIT-Fatigue scores through week 24
Clinical response Effect Guselkumab 100mg Q4W vs placebo
Estimate (95% CI)
Guselkumab 100mg Q8W vs placebo
Estimate (95% CI)
ACR20 DISCOVER-1 NDE 2.60 (0.58, 4.46)* 0.36 (−1.72, 2.40)
NIE 1.20 (0.27, 2.31)* 2.75 (1.38, 4.32)*
Total effect 3.79 (1.94, 5.44)* 3.12 (1.05, 5.15)*
% Indirect (mediated) effect 31.5% 88.3%
% Direct effect 68.5% 11.7%
DISCOVER-2 NDE 2.49 (0.96, 4.14)* 1.44 (−0.11, 2.97)
NIE 1.09 (0.42, 1.95)* 2.53 (1.62, 3.64)*
Total effect 3.58 (2.10, 5.05)* 3.97 (2.41, 5.53)*
% Indirect (mediated) effect 30.3% 63.7%
% Direct effect 69.7% 36.3%
MDA DISCOVER-1 NDE 2.84 (0.97, 4.71)* 2.34 (0.24, 4.45)*
NIE 0.78 (0.16, 1.40)* 0.74 (0.09, 1.39)*
Total effect 3.62 (1.76, 5.49)* 3.08 (0.99, 5.18)*
% Indirect (mediated) effect 21.6% 24.0%
% Direct effect 78.4% 76.0%
DISCOVER-2 NDE 3.13 (1.63, 4.63)* 2.67 (1.09, 4.26)*
NIE 0.28 (0.07, 0.50)* 1.06 (0.49, 1.64)*
Total effect 3.41 (1.96, 4.86)* 3.74 (2.13, 5.34)*
% Indirect (mediated) effect 8.3% 28.5%
% Direct effect 91.7% 71.5%
Change in CRP DISCOVER-1 NDE 3.19 (1.37, 5.02)* 2.51 (0.52, 4.50)*
NIE 0.42 (−0.03, 0.86) 0.56 (−0.10, 1.22)
Total effect 3.61 (1.74, 5.47)* 3.06 (0.95, 5.17)*
% Indirect (mediated) effect 11.6% 18.2%
% Direct effect 88.4% 81.8%
DISCOVER-2 NDE 2.88 (1.36, 4.41)* 3.20 (1.62, 4.79)*
NIE 0.49 (−0.07, 1.05) 0.60 (0.05, 1.14)*
Total effect 3.37 (1.93, 4.81)* 3.80 (2.24, 5.36)*
% Indirect (mediated) effect 14.5% 15.7%
% Direct effect 85.5% 84.3%
ACR20 and MDA were dichotomous mediators; change in CRP was a continuous mediator
ACR20 ≥20% improvement in American College of Rheumatology criteria, CRP C-reactive protein, FACIT Functional Assessment of Chronic Illness Therapy, MDA
minimal disease activity, NDE natural direct effect (effect on FACIT-F beyond the effect on the clinical response), NIE natural indirect effect (effect on FACIT-F
mediated by clinical response), Q4W every 4 weeks, Q8W every 8 weeks
*P vs placebo < 0.05
Rahman et al. Arthritis Research & Therapy          (2021) 23:190 Page 9 of 12clinically meaningful improvement in FACIT-Fatigue
score [21] at week 24, cumulative distribution curves
also demonstrated a clear separation of both guselku-
mab groups from placebo over a broad range of cut-
points of improvement (≥2 to ≥12) during this time-
frame. In addition, by conducting analyses separately for
the similarly designed DISCOVER-1 and DISCOVER-2
studies, we were able to evaluate the consistency of
guselkumab’s effect on fatigue across a broad population
of patients with differing degrees of active PsA at the
study outset. Unfortunately, cross-study comparisonswith other biologics are constrained by differences in
study designs, patient populations, and scales used to
measure fatigue.
Mediation analysis is a statistical technique employed
to explore mechanisms underlying an observed relation-
ship between an exposure variable and an outcome vari-
able and how they relate to a third intermediate variable,
the mediator [26, 27]. To investigate the mechanism by
which guselkumab improves fatigue in PsA, we
employed this computational model to distinguish direct
effects of guselkumab treatment on fatigue from indirect
Rahman et al. Arthritis Research & Therapy          (2021) 23:190 Page 10 of 12effects, i.e., those influenced by improvement in an inter-
mediate factor such as signs and symptoms of arthritis
and/or systemic inflammation. Achievement of an
ACR20 response was the prespecified mediator in these
analyses, and post hoc analyses utilized achievement of
MDA or changes in serum CRP levels as alternative me-
diators of guselkumab’s effect on FACIT-Fatigue scores.
Results of the prespecified analysis indicated approxi-
mately one-third and two-thirds of the improvement in
fatigue with guselkumab Q8W and Q4W, respectively,
at week 24 was independent of the drug’s effect on
achievement of ACR20 response and therefore not sim-
ply mediated by improvement in this particular constel-
lation of PsA signs and symptoms. Results of the post
hoc analyses assessing achievement of MDA or changes
in serum CRP levels as mediators also indicated that
guselkumab exerted an effect on fatigue independent
from achievement of MDA response and altered sys-
temic inflammation. Relative to mean change data, re-
sults across the conducted mediation analyses indicated
the direct treatment effect of guselkumab on FACIT-
Fatigue score was numerically greater with Q4W than
Q8W dosing. These differences, which are inconsistent
across outcome variables tested, could derive from small
numerical differences in baseline disease characteristics
across treatment groups and/or data variability across
the various ACR and MDA components. Although find-
ings are applied to both guselkumab dosing regimens,
across the three potential mediators assessed, results are
based on a statistical technique and should be inter-
preted with caution. Additional analyses are warranted
to explore any true differences between the two guselku-
mab dosing regimens.
Fatigue is highly subjective, and the source is complex,
undefined, and likely multidimensional [4]. Despite this,
to develop more effective treatments, it is important to
understand the mechanism of fatigue in PsA. Fatigue is
a frequent symptom in inflammatory rheumatic diseases
[2, 3] and has been postulated to be mediated in part by
Th1 and Th17 pro-inflammatory cytokines in multiple
sclerosis, another inflammatory autoimmune disorder
[45]. Given that the IL-23/Th17 pathway is crucial to
PsA pathogenesis and targeted biologic therapy [46] and
that guselkumab specifically targets IL-23 through its
p19 subunit, the direct effects of guselkumab on FACIT-
Fatigue scores in patients with PsA could derive from its
action on yet-to-be identified fatigue-specific inflamma-
tory pathways, either alone or in combination with other
factors. Further exploration is clearly needed.
Improvements in FACIT-Fatigue score in patients with
PsA have also been observed with other biologics target-
ing different pathways [12, 39]. However, due to inher-
ent differences in study populations, designs, and
assessment tools, direct comparisons between treatmentscannot be made without a head-to-head comparitive
trial. As such, results of the current analysis are specific
to the effects of guselkumab and cannot be compared
with or extrapolated to effects of other biologic therap-
ies. Additional research utilizing data from active-
comparator studies may help to differentiate biologics in
their ability to treat fatigue; such information would be
useful to both physicians and patients in selecting treat-
ments. As mentioned above, we employed computa-
tional methods in an effort to distinguish direct from
indirect effects of guselkumab on fatigue. Results of
these mediation analyses indicate guselkumab’s effect on
fatigue is not solely dependent on its effects on achieve-
ment of ACR or MDA response, or CRP. However, these
findings should be interpreted with caution given the
multifactorial causation of fatigue. Future research will
need to evaluate the effect of guselkumab on additional
potential drivers of fatigue, e.g., activity, sleep, mental
health, and anemia. Also, given the contribution of fa-
tigue to disease burden in patients with psoriasis [47],
future analyses should investigate direct treatment ef-
fects on fatigue in cohorts of patients with psoriasis. Fi-
nally, despite employing a conservative estimate of
minimal clinically meaningful improvement in FACIT-
Fatigue sores, we observed a relatively high placebo re-
sponse rate, particularly in DISCOVER-2. However, the
cumulative distribution curves confirmed that both
guselkumab dosing regimens demonstrated clear separ-
ation from placebo across a range of change cut-points
(i.e., ≥2 to ≥12).
Conclusions
Taken together, results of these analyses indicate a
strong impact of guselkumab on the fatigue of PsA when
assessed via the FACIT-Fatigue instrument. Although
further research is needed to more fully characterize the
mechanism by which guselkumab improves patient fa-
tigue, our findings may further inform treatment deci-
sions [16], additional research on this topic, and future
consensus deliberations surrounding PsA core set
assessments.
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